Inobrodib

N/A

Report date: 2026/04/16 20:00:17
NME

Base Information

Drug NameInobrodib
Drug Alias NameCCS-1477
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActioncAMP-response element binding protein inhibitorsHistone acetyltransferase p300 inhibitors
TargetscAMP-response element binding proteinHistone acetyltransferase p300
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwedenNetherlands +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellcentric Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCellcentric Ltd
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A